AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
Log in

NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News

$60.59
-2.18 (-3.47 %)
(As of 07/9/2020 12:37 PM ET)
Add
Compare
Today's Range
$59.66
Now: $60.59
$63.19
50-Day Range
$55.75
MA: $64.32
$70.39
52-Week Range
$31.30
Now: $60.59
$72.03
Volume5,546 shs
Average Volume276,851 shs
Market Capitalization$2.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.28 per share

Profitability

Net Income$-72,130,000.00

Miscellaneous

Employees50
Market Cap$2.18 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.

Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

How has Turning Point Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TPTX stock has increased by 49.9% and is now trading at $60.7650. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Turning Point Therapeutics.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics (NASDAQ:TPTX) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($0.66) by $1.03. View Turning Point Therapeutics' earnings history.

What price target have analysts set for TPTX?

7 analysts have issued 1-year target prices for Turning Point Therapeutics' stock. Their forecasts range from $56.00 to $88.00. On average, they expect Turning Point Therapeutics' stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View analysts' price targets for Turning Point Therapeutics.

Has Turning Point Therapeutics been receiving favorable news coverage?

News coverage about TPTX stock has trended negative on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Turning Point Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Turning Point Therapeutics.

Are investors shorting Turning Point Therapeutics?

Turning Point Therapeutics saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 2,740,000 shares, a decline of 16.2% from the May 31st total of 3,270,000 shares. Based on an average daily volume of 412,300 shares, the short-interest ratio is presently 6.6 days. Approximately 9.2% of the company's shares are short sold. View Turning Point Therapeutics' Current Options Chain.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include AbbVie (ABBV), Pfizer (PFE), Enterprise Products Partners (EPD), GlaxoSmithKline (GSK), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Energy Transfer LP Unit (ET), General Mills (GIS), Intel (INTC) and Johnson & Johnson (JNJ).

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
  • Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
  • Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $60.77.

How big of a company is Turning Point Therapeutics?

Turning Point Therapeutics has a market capitalization of $2.18 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.